

P22618.P01 UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No. P22618 Inventor(s) or Application Identifier: Kouichi SEKIYA, and Akihiro TAKEMIYA Title: PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF	Total Pages 10/63/09 00746 U.S. PTO 10/63/09 06/01/03
ADDRESS TO: Commissioner for Patents Mail Stop Patent Application PO Box 1450 Alexandria, VA 22313-1450		
APPLICATION ELEMENTS 1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing) 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. a. <input type="checkbox"/> Small Entity Statement(s) 3. <input checked="" type="checkbox"/> Specification [Total Pages <u>35</u>] - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <u> </u>] 5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <u>4</u>] a. <input type="checkbox"/> Newly executed (original or copy) <input type="checkbox"/> Unexecuted b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20 completed) [Note Box 6 below] i. <input checked="" type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.53(b). 6. <input checked="" type="checkbox"/> Incorporation By Reference (usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. 7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 8. <input type="checkbox"/> CD-Rom or CD-R in duplicate, large table or Computer Program (Appendix)	ACCOMPANYING APPLICATION PARTS 9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies 10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee) 12. <input type="checkbox"/> English Translation Document (if applicable) 13. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 16. <input type="checkbox"/> Figure of Drawing to be published 17. <input checked="" type="checkbox"/> Foreign priority claimed a. <input checked="" type="checkbox"/> Claim of Priority b. <input type="checkbox"/> Certified Copy of Priority Document(s) 18. <input checked="" type="checkbox"/> Assignee: <u>Mitsubishi Chemical Corporation, of Tokyo, Japan</u> 19. <input checked="" type="checkbox"/> Other: <u>Request for Deletion of Inventors Under 37 C.F.R. 1.63(d)(2) and Naming of Inventive Pursuant to 37 C.F.R. 1.53(B)</u> _____ _____ _____	
20. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. <u>09/926,477</u> , filed <u>May 9, 2000</u> . Prior application information: Examiner: _____ Group Art Unit: _____		
21. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <u> </u> continuation-in-part, <u> </u> continuation, <u> </u> divisional, of Application No. <u> </u> / <u> </u> filed <u> </u>		

Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.
 1950 Roland Clarke Place
 Reston, VA 20191
 (703) 716-1191

8/1/03
 Date

Bruce H. Bernstein
 Signature

Bruce H. Bernstein, Reg. No. 29,027
 Typed or Printed Name



FEE TRANSMITTAL

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Herewith
First Named Inventor	Kouchi SEKIYA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	P22618

TOTAL AMOUNT OF PAYMENT (\$)750.00

METHOD OF PAYMENT (check one)

FEE CALCULATION (continued)

1. ☒ The U.S. Patent and Trademark Office is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 19-0089Deposit Account Name GREENBLUM & BERNSTEIN, P.L.C.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3))
- ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)
- ☐ Applicant Claims Small Entity Status See 37 CFR 1.27.

2. ☒ Payment Enclosed:

☒ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION (fees effective 01/01/03)

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	<u>750.00</u>
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 750.00

2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
Independent Claims	<u>3</u> - <u>3</u> = <u>0</u>	<u>0</u> x <u>84</u> = <u>0.00</u>	<u>0.00</u>
Multiple Dependent Claims	<u>0</u> x <u>280</u> = <u>0.00</u>		<u>0.00</u>

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim
1204	84	2204	42	Reissue independent claims over original patent
1205	18	2205	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	2053	65	Non-English specification	
1812	2,520	2012	2,520	For filing a request for reexamination	
1804	920*	2004	920*	Requesting publication of SIR	
1805	1,840*	2005	1,840*	Prior to Examiner action	
1251	110	2251	55	Requesting publication of SIR after Examiner action	
1252	410	2252	205	Extension for response within 1st month	
1253	930	2253	465	Extension for response within 2nd month	
1254	1,450	2254	725	Extension for response within 3rd month	
1255	1,970	2255	985	Extension for response within 4th month	
1401	320	2401	160	Extension for response within 5th month	
1402	320	2402	160	Notice of Appeal	
1403	280	2403	140	Filing a brief in support of an appeal	
1451	1,510	2451	1,510	Request for oral hearing	
1452	110	2452	55	Petition to institute a public use proceeding	
1453	1,300	2453	650	Petition to revive unavoidably abandoned application	
1501	1,300	2501	650	Petition to revive unintentionally abandoned application	
1502	470	2502	235	Utility issue fee (or reissue)	
1503	630	2503	315	Design issue fee	
1460	130	2460	130	Plant issue fee	
1807	50	2807	50	Petitions to the Commissioner	
1806	180	2806	180	Petitions related to provisional applications	
8021	40	8021	40	Submission of IDS	
1809	750	2809	375	Recording each patent assignment per property (times number of properties)	
1810	750	2810	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1801	750	2801	375	For each additional invention to be examined (37 CFR 1.129(b))	
1802	900	2802	900	Request for Continued Examination (RCE)	
				Request for expedited examination of a design application	
Other fee (specify) _____					
Other fee (specify) _____					

*Reduced by Basic Filing Fee paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name Bruce H. BernsteinReg. Number 29,027Signature BernsteinDate 8/1/03

Deposit Account User ID

P22618.A01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kouichi SEKIYA et al.

Group Art Unit : 1624

Appln. No : Not Yet Assigned

Examiner : Unknown

Filed : Concurrently Herewith

For : PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE
ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF

**REQUEST FOR DELETION OF INVENTORS UNDER 37 C.F.R. 1.63(d)(2)
AND
NAMING OF INVENTIVE ENTITY PURSUANT TO 37 C.F.R. 1.53(B)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.53(b) and 37 C.F.R. 1.63(d)(2), Applicants hereby request
deletion of the following inventor named in parent Application No. 09/926,477, filed May 9,
2000 as PCT/JP00/02952:

Masahiro OHSHIMA.

Accordingly, Kouichi SEKIYA and Akihiro TAKEMIYA are named as inventors of the
present application.

Therefore, the inventors of the presently claimed invention are:


Kouichi SEKIYA, and

Akihiro TAKEMIYA.

P22618.A01

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Kouichi SEKIYA et al.


Bruce H. Bernstein
Reg. No. 29,027

Spec. 33,094

August 1, 2003
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191